HK Grey Market | Metis TechBio Soars 191%; Impact Therapeutics Jumps 41%

Tiger Newspress
05/12

Metis TechBio, one of the "Top Three AI Drug Discovery" companies in Mainland China, soared 191% in Hong Kong’s grey market trading.

Founded in 2020, Metis TechBio focuses on the delivery and application of payloads across a range of biological systems, using artificial intelligence-powered nanotechnology to advance healthcare solutions.

Chinese cancer-drug developer Impact Therapeutics jumped 41% in Hong Kong’s grey market trading.

Founded in 2009, Impact Therapeutics is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10